鐵死亡標靶治療的全球市場：市場機會與臨床試驗的見解 (2024)

迄今為止，在這種創新療法的變革潛力以及研發方面的重大進展的推動下，全球鐵死亡標靶治療領域經歷了前衛的成長。這就是世界各地的製藥和生物技術公司紛紛加入的原因，包括 MitoImmune Therapeutics 和 PTC Therapeutics。

此外，一些製藥公司和創投公司也在研究和開發針對鐵死亡的治療方法。例如，總部位於美國的 Kojin Therapeutics 成立於 2020 年。除了鐵死亡生物學之外，該公司還致力於在細胞狀態方面取得革命性突破，旨在利用這些發現開發一流的競爭性藥物，用於治療許多患有癌症、心血管、免疫學和退化性疾病的患者。

此外，Prothegen 也是一家將於 2021 年成立的生技新創公司。Prothegen 由發現鐵死亡概念的世界領導者創立，隨著鐵死亡領域多年來的不斷擴展，Prothegen 開發了一種突破性的鐵死亡技術，可以精確地控制細胞死亡。

本報告檢視了全球鐵死亡標靶治療市場，並提供了市場概況，包括藥物趨勢、臨床試驗趨勢、區域趨勢以及進入市場的公司競爭格局。

目錄

第 1 章：鐵死亡標靶治療併發症的闡明

• 鐵死亡標靶治療概述
• 鐵死亡標靶治療的歷史與發展

第二章鐵死亡標靶治療的臨床需求

第 3 章鐵死亡作為診斷與預後生物標記的雙重作用

第 4 章：鐵死亡管理的突破性策略

• 小分子
• 藥品再利用
• 光動力療法
• 細胞外囊泡

第五章 鐵死亡標靶治療（依適應症）：臨床趨勢與創新

• 癌症
• 自體免疫疾病與發炎性疾病
• 病毒感染
• 神經系統疾病
• 心臟疾病

第六章 全身性鐵死亡標靶治療臨床試驗概述

• 相別
• 依國家
• 依公司
• 依指示
• 依優先權

第7章系統性鐵死亡標靶治療臨床試驗的啟示

• 調查
• 臨床前
• 第一階段
• 第二階段
• 第三階段

第八章 全球鐵死亡標靶治療市場現況及進展

• 當前市場概況
• 未來市場預測

第九章 鐵死亡標靶治療趨勢分析：分地區

• 美國
• 中國
• 歐洲
• 韓國

第 10 章 鐵死亡候選者獲得 FDA 和 EMA 指定

第11章鐵死亡標靶治療的組合策略

• 與常規治療結合
• 光動力療法和磁場的結合

第12章用於開發先進鐵死亡標靶治療的平台

第十三章鐵死亡標靶治療全球市場動態

• 市場驅動力
• 市場課題

第14章競爭格局

• Kojin Therapeutics
• MitoImmune Therapeutics
• Prothegen
• PTC Therapeutics
• Sumitomo
• Tharimmune

Global Ferroptosis Targeting Therapy Market Opportunity and Clinical Trials Insight 2024 Report Highlights:

• Global and Regional Market Opportunity Analysis
• Clinical Trials Insight On Key Therapies In Trials: > 10 Therapies
• Ferroptosis Targeting Therapy Clinical Trials Insight By Company, Country, Indication and Phase
• Ferroptosis Targeting Therapy Clinical Trends and Innovations Outlook By Indications
• Key Therapies Clinical Study Initiation and Completion Year Insight
• Ferroptosis Candidates Granted FDA and EMA Designations: Orphan, Fast Track

The panorama of scientific targeting therapy landscape is countersigning a transmogrification swing as headways in therapeutic research in conjugation with technological advancement pave the way for more precise and tailored treatment approaches. Midst the notable developments is the growing recognition of the prerequisite for ferroptosis targeted therapy, a recently discovered form of regulated cell death, has garnered historic consideration in the field of cancer research as well as drug development. Presently, no ferroptosis targeting therapies have entered into the commercial global market, thereby, representing an opportunity for pharma companies to advance the realm of ferroptosis targeted therapy.

Hitherto, the global sector of ferroptosis targeted therapy has acknowledged an avant-garde growth, fueled by the noteworthy progression in research and development, in addition to the transformative potential of this innovative treatment modality. On that account, several pharma in addition to biotech companies across the globe, comprising MitoImmune Therapeutics, and PTC Therapeutics.

Coupled with that, several pharma companies as well as ventures are additionally shepherding superfluous research and development for ferroptosis targeting therapies. For instance, Kojin Therapeutics, based in the US, was founded in 2020. The company is leveraging revolutionary findings in cell-state in addition to ferroptosis biology with the intention to develop first-in-class contenders for the treatment of numerous patients suffering with cancer, and cardiovascular, immunologic, and degenerative diseases.

Moreover, Prothegen is another biotech start-up business that is launched in 2021. Founded by world leaders in ferroptosis who discovered the concept of ferroptosis, Prothegen aims to deliver ground-breaking ferroptosis therapies to control cell death with exquisite accuracy, indicating that the domain of ferroptosis is augmenting year by year.

Owing to positive outcomes observed in preclinical as well as translational studies led to initiation of clinical trials. For instance, vatiquinone (PTC743), a small molecule, first-in-class selective inhibitor of 15 lipoxygenase (15-LO), is currently in open-label, phase III safety study (NCT05218655) to assess the safety of vatiquinone in participants with inherited mitochondrial disease. It is an interventional study which has an estimated enrollment of 100 participants. The clinical research was begun in June 2022 and is expected to be complete by March 2025.

Data from gathering evidences suggests the participation of ferroptosis in various pathological conditions apart from cancer, for example autoimmune disorders, inflammation, neurodegenerative diseases, ischemic injuries, kidney illness and age related disorders, has expanded the potential applications of ferroptosis targeting therapy. For that reason, healthcare professionals are scrutinizing the therapeutic potential of targeting ferroptosis in these diverse contexts, further fueling the market for ferroptois targeting therapies.

Interalia, clinical research has examined the usage of ferroptosis targeting therapies to disrupt viral replication, demonstrating efficacy against infections caused by viruses. These findings open avenues for the development of antiviral therapeutics. For instance, preliminary studies conducted by scientists at MitoImmune Therapeutics demonstrated that MIT-001, an anti-inflammatory and anti-necrotic agent, can additionally being used to treat viral infections such as COVID-19.

Subsequently, another study accomplished by MitoImmune Therapeutics in collaboration with Stand Up Therapeutics, in April 2024, showed in vitro broad-spectrum antiviral activity of MIT-001 to treat severe acute respiratory syndrome coronavirus 2 and multiple zoonotic viruses. This opens a novel prospect in healthcare sector, in future, to investigate ferroptosis therapy in various other indications.

As well as, the prospective for amalgamation therapies involving ferroptosis targeting agents in synergy with other established cancer treatments has garnered cognizance. Synergistic effects have been observed when ferroptosis inducers are combined with chemotherapeutic agents, radiation therapy, nanotechnology or targeted therapies, potentially enhancing therapeutic efficacy and improving patient outcomes.

As a final point, all elucidations aforesaid epitomize that the global ferroptosis market is growing at a trailblazing gait and is predictable to multiply additional in the forthcoming years. The presences of giant pharma companies (PTC Therapeutics) in conjugation with contribution from other corporations and several startup business, like Kojin, MitoImmune Therapeutics, Sumitomo Pharma and Prothegen, exemplifies that the domain of ferroptosis targeting therapies is evolving. In conclusion, PTC Therapeutics is frontrunner in the global clinical together with commercial market due to the fact that its two ferroptosis inhibiting contenders, utreloxastat and vatiquinone, are expected to enter into the market into future as both the candidates have presented topline outcomes in late stage clinical trials.

Table of Contents

1. Deciphering Complicacies For Ferroptosis Targeting Therapy

• 1.1 Outline to Ferroptosis Targeting Therapy
• 1.2 Chronicle & Development of Ferroptosis Targeting Therapy

2. The Clinical Necessity For Ferroptosis Targeting Therapy

3. Dual Role Of Ferroptosis As Diagnostic & Prognostic Biomarker

4. Breakthrough Strategies For Ferroptosis Management

• 4.1 Small Molecules
• 4.2 Drug Repurposing
• 4.3 Photodynamic Therapy
• 4.4 Extracellular Vesicles

5. Ferroptosis Targeting Therapy By Indications: Clinical Trends & Innovations

• 5.1 Cancer
• 5.2 Autoimmune & Inflammatory Diseases
• 5.3 Viral Infections
• 5.4 Nervous system disorders
• 5.5 Cardiac Diseases

6. Global Ferroptosis Targeting Therapy Clinical Trials Overview

• 6.1 By Phase
• 6.2 By Country
• 6.3 By Company
• 6.4 By Indication
• 6.5 By Priority Status

7. Global Ferroptosis Targeting Therapy Clinical Trials Insight

• 7.1 Research
• 7.2 Preclinical
• 7.3 Phase I
• 7.4 Phase II
• 7.5 Phase III

8. Global Ferroptosis Targeting Therapy Current Market Trend & Developments

• 8.1 Current Market Outline
• 8.2 Future Market Forecast

9. Ferroptosis Targeting Therapy Trend Analysis By Region

• 9.1 US
• 9.2 China
• 9.3 Europe
• 9.4 South Korea

10. Ferroptosis Candidates Granted FDA & EMA Designations

11. Combination Stratagems For Ferroptosis Targeting Therapies

• 11.1 Combinations with Conventional Therapies
• 11.2 Combinations with Photodynamic Therapies & Magnetic Field

12. Platforms Used For Developing Advanced Ferroptosis Targeting Therapy

• 12.1 Ferroptosis & Inflammation Platform
• 12.2 MIT Platform
• 12.3 Kojin Ferroptosis Platform

13. Global Ferroptosis Targeting Therapy Market Dynamics

• 13.1 Market Drivers
• 13.2 Market Challenges

14. Competitive Landscape

• 14.1 Kojin Therapeutics
• 14.2 MitoImmune Therapeutics
• 14.3 Prothegen
• 14.4 PTC Therapeutics
• 14.5 Sumitomo
• 14.6 Tharimmune

List of Figures

• Figure 1-1: Role of Ferroptosis in Various Indications
• Figure 1-2: Progression of Cell Death
• Figure 2-1: Need of Ferroptosis Therapy
• Figure 3-1: Ferroptosis Related Protein as Diagnostic & Prognostic Marker
• Figure 4-1: Therapeutic Modality for Ferroptosis
• Figure 5-1: Plant Products Used to Induce Ferroptosis in Cancer Treatment
• Figure 5-2: CNSI-Fe (II) Phase I Study - Initiation & Completion Year
• Figure 5-3: N6F11 (Ferroptosis Inducer) - Mode of Action
• Figure 5-4: MIT-001 Phase II (NCT05493800) Study - Initiation & Completion Year
• Figure 5-5: MIT-001 - Preclinical Stage for Viral Infections
• Figure 5-6: Vatiquinone (NCT05515536) Phase III Study - Initiation & Completion Year
• Figure 5-7: Utreloxastat Phase II Study - Initiation & Completion Year
• Figure 6-1: Global - Ferroptosis Targeting Therapy Clinical Trials By Phase (Numbers), 2024
• Figure 6-2: Global - Ferroptosis Targeting Therapy Clinical Trials By Country (Numbers), 2024 - 2030
• Figure 6-3: Global - Ferroptosis Targeting Therapy Clinical Trials By Company (Numbers), 2024
• Figure 6-4: Global - Ferroptosis Targeting Therapy Clinical Trials By Indication (Numbers), 2024 - 2030
• Figure 6-5: Global - Ferroptosis Targeting Therapy Clinical Trials By Priority Status (Numbers), 2024
• Figure 8-1: Key Players - Ferroptosis
• Figure 8-2: Rudolf Virchow Centre & Julius-Maximilians-Universitat Wurzburg Professors received Grant by European Research Council
• Figure 8-3: Ferroptosis - Future Market
• Figure 9-1: Vatiquinone Phase III (NCT05218655) Study - Initiation & Completion Year
• Figure 9-2: Utreloxastat & Vatiquinone Current Development Status
• Figure 9-3: Kojin Therapeutics Investors
• Figure 9-4: Roche Accelerator, China - Included Keen Therapeutics to Advance Ferroptosis Therapies
• Figure 9-5: MIT-001 Phase II (NCT04651634) Study - Initiation & Completion Year
• Figure 11-1: Ferroptosis Combinations with Other Therapies
• Figure 12-1: Kojin Therapeutics - Ferroptosis Platform
• Figure 13-1: Ferroptosis - Market Drivers
• Figure 13-2: Ferroptosis - Market Challenges

List of Tables

• Table 4-1: Therapeutic Compounds Inducing/Inhibiting Ferroptosis
• Table 5-1: Reversing Therapies Resistance by Ferroptosis Inducing Compounds for Cancer
• Table 5-2: Role of Ferroptosis in Autoimmune & Inflammatory Disease
• Table 5-3: Anti-Ferroptosis Therapeutic Options for Autoimmune & Inflammatory Disease
• Table 5-4: Ferroptosis Effector & its Mechanism in Nervous System Disorders
• Table 5-5: Role of Ferroptosis in Cardiovascular Diseases
• Table 10-1: Ferroptosis Targeting Therapies Granted FDA & EMA Designations